

# p63 Expression Is Associated with p53 Loss in Oral-Esophageal Epithelia of p53-deficient Mice<sup>1</sup>

Yasir Suliman,<sup>2</sup> Oliver G. Opitz,<sup>2</sup> Anjali Avadhani, Timothy C. Burns, Wafik El-Deiry, David T. Wong, and Anil K. Rustgi<sup>3</sup>

Division of Gastroenterology [Y. S., O. G. O., A. A., A. K. R.], Cancer Center [W. E.-D., A. K. R.], Department of Genetics [W. E.-D., A. K. R.], Abramson Family Cancer Research Institute [Y. S., O. G. O., A. K. R.], Howard Hughes Medical Institute [T. C. B., W. E.-D.], University of Pennsylvania, Philadelphia, Pennsylvania 19104-6144; Harvard School of Dental Medicine, Boston, Massachusetts 02115 [D. T. W.]; and University of Freiburg, Freiburg, 79106 Germany [O. G. O.]

## ABSTRACT

The *p53* gene family, comprising *p53*, *p63*, and *p73*, has overlapping and distinctive functional roles. These members share structural similarities allowing for dynamic interplay in the activation of genes that are important in development and key cellular functions, such as the induction of apoptosis. Whereas *p53* is a classical tumor suppressor gene, *p63* and *p73* do not share this feature in cancer formation and progression. The compensation in the expression level of these members in a background that is deficient for one of them has not been examined previously. Given the importance of *p63* in the development and differentiation of oral-esophageal stratified squamous epithelia and the absence of oral-esophageal tumors in *p53*-null mice, we postulated and describe herein that *p63* expression is associated with the loss of *p53* in a *p53*-deficient background. Both full-length and amino-truncated forms of *p63* are expressed and increased in oral-esophageal epithelia of *p53*-null mice when compared with wild-type mice, and the induction of *p21* may potentially be preserved through the increase of *p63*.

## INTRODUCTION

The *p53* tumor suppressor gene is frequently mutated in human cancers (1). Additionally, in many cancers, *p53* function is altered through binding to viral oncoproteins or abrogation of *p53* degradation by *mdm-2/hdm-2* in concert with *p19<sup>ARF</sup>/p14<sup>ARF</sup>* (2). Generally speaking, most *p53* mutations are missense, leading to stabilization of protein with gain-of-function. Some *p53* mutants can inactivate WT *p53* through hetero-oligomerization.

Recently, information has emerged about *p53* homologues, such as *p73* and *p63* (3–5), with the emphasis on *p63* in this study. Cloned through degenerate PCR, *p63* is expressed in the squamous epithelium and the thymus (6) and other tissues as well (7). *P63* has different transcripts attributable to alternative splicing ( $\alpha, \beta, \gamma$ ), and the use of different promoters results in retention of the TA<sup>4</sup> or  $\Delta N$  (4, 8, 9). Thus, these *p63* isoforms are referred to as TAp63 $\alpha, \beta, \gamma$  and  $\Delta N\alpha, \beta, \gamma$ . All *p63* isoforms contain DNA binding and hetero-oligomerization domains. However, the  $\Delta Np63$  versions lack the NH<sub>2</sub>-terminal transactivation domain but can still bind to DNA and, thus, may function as dominant negative proteins.

The TAp63 $\gamma$  and TAp63 $\beta$  transactivate promoters at levels comparable with WT *p53*, but TA-63 $\alpha$  does not contain this property (reviewed in Ref. 3). In particular, TAp63 can activate *in vitro* *p53*

responsive promoters such as *p21*, *GADD45*, *Bax*, and *mdm2* (reviewed in Refs. 8 and 10). TAp63 $\gamma$  and TAp63 $\beta$  induce apoptosis in transient transfection experiments in contrast to TA-*p63* $\alpha$  (3, 4, 6, 11). TAp63 $\gamma$  can be induced after UV irradiation (12). By contrast, the  $\Delta N$  isoforms block the functions of *p53*. This may be attributable to competition for DNA binding sites to prevent *p53* or TAp63 from binding DNA. Alternatively, it is conceivable that *p53* or TAp63 may be sequestered by  $\Delta Np63$  through the oligomerization domain or another domain (13). Precedence for interactions between *p53* family members has been established with the observation that mutant *p53* can down-regulate both *p63* and *p73* through a direct interaction with the *p53* core domain (14).

There is little evidence to suggest that *p63* acts as a tumor suppressor gene. Mutations of *p63* in human tumors are exceedingly rare (3, 5, 8, 9, 15). Patients with germ-line mutations in the DNA binding domain of *p63* result in developmental defects but not tumors (16). Additional insights into the functions of *p63* have been gained through the generation and characterization of mice in which *p63* has been ablated in embryonic stem cells through homologous recombination. *p63*-null mice are viable at birth but die several h later and are not susceptible to spontaneous tumorigenesis (17, 18). Mutant newborn mice and late stage embryos have craniofacial abnormalities, limb truncations, and a complete absence of epidermis and related appendages (17, 18). Histological analysis has revealed the absence of a stratified epithelium in the epidermis with a lack of the characteristic structure of basal, suprabasal, and cornified layers as well as hair follicles. Instead of an epidermis, *p63*<sup>-/-</sup> late stage embryos retain isolated patches of epithelial cells along the exposed dermis. Furthermore, the normally stratified squamous epithelium of tongue, esophagus, and forestomach, with the same characteristic structure of basal, suprabasal, and differentiated cells, was replaced by an unusual array of cuboidal, goblet-like epithelium.

Given that *p63* appears to be important for the development and possibly also differentiation of the stratified squamous epithelium, we postulated that *p63* may have a critical role in the maintenance of the oral-esophageal squamous epithelium by compensating for the loss of *p53* in *p53*-deficient mice.

## MATERIALS AND METHODS

**DNA Constructs.** Total RNA was extracted from the ME-180 cell line (American Type Culture Collection) using the TRIzol method (Life Technologies, Inc.). First-strand synthesis was then performed on 5  $\mu$ g of RNA using the Superscript First-Strand Synthesis system for RT-PCR (Life Technologies, Inc.). The following primers were used to amplify  $\Delta Np63$ :

$\Delta Np63\alpha$  5'ATGTTGTACCTGGAAAACAA and 5'CACTCCCCCTC-CTCTTTGA

$\Delta Np63\gamma$  5'ATGTTGTACCTGGAAAACAA and 5'CTATGGGTACTGATCGGT.

The  $\Delta Np63\alpha$  PCR product was 1761 bp, and the one for  $\Delta Np63\gamma$  was 1182 bp. These fragments were amplified using the Elongase enzyme mix (Life Technologies, Inc.). After denaturing at 94°C for 60 s, PCR consisted of 35 cycles of 94°C for 60 s, 55°C for 60 s, and 72°C for 60 s followed by 72°C for 5 min. PCR products were then analyzed on a 1% agarose gel. Nested PCR was

Received 3/21/00; accepted 6/21/01.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> Supported by NIH Grant P01 DE12467 (to A. K. R., D. W., Y. S., and O. G. O.), the Leonard and Madlyn Abramson Family Cancer Research Institute at the University of Pennsylvania Cancer Center (to A. K. R.), and Grant N01-CN-95112-72 (to A. K. R.).

<sup>2</sup> Y. S. and O. G. O. contributed equally to the work.

<sup>3</sup> To whom requests for reprints should be addressed, at 600 CRB, Division of Gastroenterology, University of Pennsylvania, 415 Curie Boulevard, Philadelphia, PA 19104-6144. Phone: (215) 898-0154; Fax: (215) 572-5412; E-mail: anil2@mail.med.upenn.edu.

<sup>4</sup> The abbreviations used are: TA, acidic NH<sub>2</sub> terminus;  $\Delta N$ , truncated NH<sub>2</sub> terminus; RT-PCR, reverse transcription-PCR; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TAMRA, 6-carboxyl-N,N,N',N'-tetramethylrhodamine; ABC, avidin-biotin peroxidase complex; WT, wild type.

Table 1 Quantitative scoring of p63 immunohistochemical staining in tongue (T) or esophagus (E) in WT or p53-null ( $p53^{-/-}$ ) mice<sup>a</sup>

|          | WT mice % positive p63 | p53-null mice % positive p63 | P     |
|----------|------------------------|------------------------------|-------|
| TA p63 E | 0.46 ± 0.15            | 0.83 ± 0.11                  | <0.05 |
| TA p63 T | 0.49 ± 0.10            | 0.75 ± 0.11                  | <0.05 |
| ΔN p63 E | 0.67 ± 0.07            | 0.88 ± 0.08                  | <0.05 |
| ΔN p63 T | 0.67 ± 0.10            | 0.89 ± 0.06                  | <0.05 |

<sup>a</sup> For comparisons of ΔN p63 immunohistochemistry, 5 WT and 5  $p53^{-/-}$  mice were used, and for full-length p63 immunohistochemistry, 5 WT and 5  $p53^{-/-}$  mice were used. Values are expressed as percentage ± standard deviation.  $P < 0.05$  is considered statistically significant.

then performed using the above ΔNp63α and ΔNp63γ primers tagged with *Xho*I and the β-actin Kozak consensus motif at the 5' prime end and *Not*I at the 3' end. Nested PCR products were then subcloned into a pCIBA vector and purified by the alkaline lysis method. The p21 promoter-luciferase reporter gene constructs used were for WT p21 (WWP-Luc) and when the p53 DNA binding sites were mutated in the context of the full-length p21 promoter (6-Luc).

**Cell Culture and Transient Transfection.** Mouse oral epithelia from WT and p53-null mice were peeled off underlying tissues after incubation with 1.5 units/ml *Dispase 1* (Boehringer Mannheim). Subsequently, the tissues were trypsinized. The cell suspension from the latter was plated and subcultivated in

serum-free medium (Life Technologies, Inc.). The mouse oral epithelial cells or keratinocytes from WT or normal (Mokn) and p53-null mice ( $p53^{-/-}$ ) were transiently transfected at 80% confluence with 0.5–1 μg of plasmid mixtures preincubated with 12 μl of Plus Reagent and 16 μl of LipofectAMINE Reagent (Life Technologies, Inc.). Cells were transfected with either WWP-Luc or 6-Luc and β-Gal constructs as well as with the ΔNp63 γ or ΔNp63 α constructs. The cells were incubated for 36 h at 37°C and then washed with PBS and harvested with Reporter lysis buffer (Promega). Luciferase and β-Galactosidase assays were performed. All experiments were performed in triplicate, and at least three independent experiments were done (results expressed as mean ± SD).

**TaqMan RT-PCR Assay.** TaqMan RT-PCR assay was conducted according to the manufacturer's instructions (PE Applied Biosystems). In brief, oligonucleotides (probes) for TaqMan RT-PCR were labeled with FAM(6-carboxyfluorescein; p21, bax) or VIC (GAPDH) and 3' prime quencher, TAMRA. The following primer and probe sequences were used:


p21 primers: 5'-CGAGAACGGTGGAACTTTGAC-3' and 5'-TCCCAGACGAAGTTGCCCT-3'

p21 probe: 6FAM-TCGTACGGAGACGCCGCTG-TAMRA


Bax primers: 5'-GGAGCAGCTTGGGAGCG-3' and 5'-AAAAGGCCCC-TGTCTTCATGA-3'

Bax probe: 6FAM-CGGGCCACCAGCTCTGAACA-TAMRA.


GAPDH primers and the Vic-labeled probe were obtained from PE Applied




(a) Wt T



(b) p53-/- T



(c) Wt E



(d) p53-/- E

Fig. 1. Full-length or TAp63 immunohistochemistry (D20 antibody) immunohistochemical staining (×40) in WT mouse tongue (A),  $p53^{-/-}$  mouse tongue (B), WT mouse esophagus (C), and  $p53^{-/-}$  mouse esophagus (D). Note the basal cell nuclear staining in  $p53^{-/-}$  tongue and esophagus.




Fig. 2.  $\Delta$ Np63 immunohistochemistry (N16 antibody) immunohistochemical staining ( $\times 40$ ) in WT mouse tongue (A),  $p53^{-/-}$  mouse tongue (B), WT mouse esophagus (C), and  $p53^{-/-}$  mouse esophagus (D). Note the basal and suprabasal cell nuclear staining in  $p53^{-/-}$  tongue and esophagus.

Biosystems. All primers and probes were designed with the use of Primer Express Version 1.0 (PE Applied Biosystems). Total RNA was isolated from tongue and esophageal epithelia of WT and  $p53$ -null mice using the TRIzol method. Total RNA ( $1 \mu\text{g}$ ) was used for reverse transcription and amplification using TaqMan Reverse Transcription Reagents according to manufacturer's protocol (PE Applied Biosystems). A master mix of TaqMan reagents was prepared, and  $10 \text{ ng}$  of each reverse transcription sample was used in the TaqMan PCR reaction. Each tube contained both a gene probe and primers and a GAPDH control probe and primer. Each sample was done in quadruplicate. Reactions in which reverse transcriptase was not added to the reverse transcription reaction were used to control for genomic contamination. The increase in fluorescence was proportional to the concentration of template in the PCR. The standard curve method was used to quantitate amounts of each gene relative to the GAPDH amount in each reaction according to the manufacturer's protocol (PE Applied Biosystems). Reactions were carried out in 96-well plates using the ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems).

**Histology and Immunohistochemistry.** Age-matched (4–5 months), WT, and  $p53$ -deficient mice littermates from the same BL/6 background strain were sacrificed. Oral-esophageal tissues were fixed in 4% paraformaldehyde, embedded in paraffin, and tissue sections were stained with H&E in a manner similar to our previous studies (19). Immunohistochemical staining was performed in mouse tongue and esophageal tissue sections by the ABC method





Fig. 3. Western blot analysis of WT and  $p53^{-/-}$  mice tongues and esophagi for full-length TAp63 (A) and  $\Delta$ Np63 (B). Note the increased level of full-length p63 and  $\Delta$ Np63 in epithelial protein lysates derived from  $p53^{-/-}$  mice. Equal loading and transfer of proteins were confirmed with Ponceau S staining of membranes and reprobing with an actin antibody (data not shown).

Fig. 4. TaqMan assay of p21 mRNA expression level in WT and p53-null tongue and esophagus. Note that p21 mRNA expression level in p53-null tongue is comparable with that of WT tongue. p21 mRNA expression level is increased in p53-null esophagus compared with WT esophagus.



using the Vectastain Elite ABC kit (Vector Laboratories) as described previously (20). Sections (3–5 μm) were mounted on adhesive-coated slides, deparaffinized, and rehydrated through xylene and alcohol. After rinsing in tap water and PBS, slides were placed in plastic Coplin jars containing 10 mM citrate buffer. Jars were covered with loose-filling caps and heated in the microwave oven for 20 min to unmask antigen. Endogenous peroxidase was blocked with 3% H<sub>2</sub>O<sub>2</sub> in methanol for 5 min. Sections were blocked with either 5% rabbit serum or protein blocking agent (Immunotech) for 15 min after being cooled. Slides were then incubated with primary antibody (4A4 for full-length p63 and Ab-1 for ΔNp63 from PharMingen and Oncogene Science, respectively) overnight at 4°C, washed in PBS, and incubated with the corresponding biotinylated secondary antibody for 60 min at room temperature. After PBS washes, sections were incubated with ABC Elite reagent for 5 min at room temperature, and reaction products were developed using diaminobenzidine tetrahydrochloride (Sigma Chemical Co.) as chromogen and counterstained with hematoxylin.


Three ×40 power fields were counted on each slide. The positively stained nuclei were counted and divided by the total number of nuclei per high power field, and a mean was calculated. Of note, cytoplasmic staining was rare. Two independent scorers were blinded to the slide source when doing the evaluation. Student's *t* test was used for statistical analysis, and *P* < 0.05 was considered statistically significant. Additionally, staining intensity was designated from 1–3, where 1 is weak, 2 is moderate, and 3 is strong based upon similar qualitative approaches described previously (20).

**Western Blot Analysis.** The tongue or esophageal mucosa was immediately dissected away from the muscularis propria after incubation in 1.5 units/ml *Dispase 1* (Boehringer Mannheim) overnight at 4°C. The epithelium was peeled off with forceps, minced, and lysed in ELB buffer [50 mM HEPES (pH 7.4), 0.1% NP-40, and 250 mM NaCl] with protease inhibitors (5 μg/ml aprotinin, 100 μg/ml phenylmethane sulfonyl fluoride, and 5 μg/ml leupeptin) and phosphatase inhibitors (5 μg/ml sodium vanadate and 10 mM sodium fluoride) for 45 min on ice. The lysates were centrifuged at 13,000 rpm at 4°C for 15 min, and supernatants were collected. Total protein (10 μg) of each sample was separated on a 10% SDS-polyacrylamide gel. After electrophoresis, proteins were transferred to Immobilon membranes (Millipore) at 100 V for 1 h at 4°C. Blocking was performed in 5% milk, 10 mM Tris pH 7.4, 150 mM NaCl, and 0.2% Tween 20 overnight at 4°C. Primary antibody against p63 (D20 for TAp63 and N16 for ΔNp63; Santa Cruz Biotechnology, Santa Cruz, CA) was used at a 1:2,000 dilution. Secondary antibody was peroxidase conjugated sheep anti-goat immunoglobulin (1:2,000 dilution; Sigma Chemical Co.). The detection system was enhanced chemiluminescence (Amersham). Equal loading of proteins was confirmed by Ponceau S staining of the membranes and reprobing the membranes with an actin antibody.

**RESULTS**

Age-matched WT and p53-null mice were assessed for histopathological changes in the oral-esophageal squamous epithelium and not

Fig. 5. TaqMan assay of Bax mRNA expression level in WT and p53-null tongue and esophagus. Note that bax mRNA expression in p53-null tongue is comparable with that of WT tongue. Bax mRNA expression level is increased in p53-null esophagus compared with WT esophagus.






Fig. 6. Cotransfection of WT p21 promoter-luciferase reporter gene and WT p53, dominant negative p53,  $\Delta$ Np63 $\gamma$ , or  $\Delta$ Np63 $\alpha$  into either WT or normal oral keratinocytes (A) versus p53-null oral keratinocytes (B). Luciferase activity was standardized to  $\beta$ -galactosidase activity and expressed as fold-induction. Transfections were carried out in triplicate and done in at least three independent experiments (mean  $\pm$  SD).

found to have any evidence of hyperplasia, dysplasia, carcinoma, or impaired squamous epithelial differentiation. These mice were then assessed for p63 expression using immunohistochemical approaches to detect both the full-length (TA) and amino-truncated ( $\Delta$ N) versions of p63, respectively. The antibodies do not cross-react with each other but do recognize the  $\alpha$ ,  $\beta$  and  $\gamma$  isoforms for their respective TAp63 or  $\Delta$ Np63 proteins. This analysis led to the determination that both TAp63 and  $\Delta$ Np63 are expressed in oral-esophageal epithelia of WT and p53-null mice (Table 1; Figs. 1 and 2). Additionally, there is increased expression of both TAp63 and  $\Delta$ Np63 in the oral-esophageal epithelia of p53-null mice when compared with their age-matched WT littermates, in a statistically significant fashion (Table 1). There also appears to be predominance of TAp63 in basal cells compared with  $\Delta$ Np63 in this compartment (Figs. 1 and 2). Further-

more, the intensity of p63 staining, a qualitative parameter, appears to be enhanced in p53-null mice compared with their WT counterparts (Figs. 1 and 2).  $\Delta$ Np63 staining intensity was moderate to high in tongues and esophagi of p53-null mice compared with weak in WT mice. TAp63 showed a moderate to high staining intensity in the same tissues of p53-null mice compared with a weak to moderate staining intensity in WT mice.

As further and independent corroboration of p63 expression, tongue and esophageal epithelial cells from both WT and p53-null mice were isolated from which protein lysates were used for Western blot analysis. This revealed that TAp63 protein is expressed at a higher level in oral (8.5 $\times$ ) and esophageal (1.3 $\times$ ) epithelial cells from p53-null mice compared with WT mice (Fig. 3). It is possible that the molecular mass corresponding to p63 represents posttranslational modifica-

tions and/or recognition of different isoforms as observed by others (7). Np63 expression was also increased in oral (4×) and esophageal (3×) esophageal epithelial cells from p53-null mice compared with WT mice (Fig. 3).

Because it is known that p21 and Bax are targets of p53 *in vitro*, we postulated that p21 and Bax may still be expressed in the oral-esophageal epithelia of p53-null mice, possibly as the result of the associated increase of TAp63 noted by immunohistochemical and Western blot analyses. Indeed, quantitative measurement of p21 and Bax mRNA levels by the TaqMan assay revealed that p21 and Bax mRNA expression levels in tongues of p53-null mice is comparable with that in WT mice (Figs. 4 and 5). Additionally, the expression level of p21 as well as Bax mRNA in p53-null esophagus was 2-fold higher when compared with that of WT esophagus (Figs. 4 and 5).

To investigate further the functional consequences of p63-mediated transactivation of a p53-responsive promoter, we successfully established oral epithelial cells in culture from WT and p53-null mice. These cells have the expected cytokeratin profile (keratins 5, 14, 4, and 13), and the p53-null cells do not express p53 (data not shown). As expected, dominant-negative p53, ΔNp63γ, and ΔNp63α suppress p21-mediated transactivation in WT or normal oral keratinocytes, in contrast to WT p53 (Fig. 6). However, in p53-null oral keratinocytes, WT p53 transactivates the p21 promoter, but ΔNp63γ no longer suppresses the p21 promoter (Fig. 6). Dominant-negative p53 and ΔNp63α retain their abilities to suppress the p21 promoter in a p53-null background. These results suggest there may be functional differences between ΔNp63γ and ΔNp63α in transactivation of the p21 promoter.

## DISCUSSION

The evidence for p63 as a tumor suppressor gene is not compelling as that for p53. P63 mutations are extremely rare in human cancers and derived cell lines (15), although germ-line mutations in p63 are associated with the ectrodactyly, ectodermal dysplasia and cleft lip/palate (EEC) syndrome (16). This would appear to suggest that p63 is important in different types of cellular functions, and there are differences in the physiological roles of p53 family members, which may, in part, reflect differences in interactions with each other (16).

Recently, analysis of p73-null mice revealed unique roles for p73 in neurogenesis, sensory pathways, and homeostatic control (13, 14). p63 is relatively tissue restricted, and targeted disruption through homologous recombination in mice leads to a dramatic phenotype, part of which is consistent with a critical role in squamous epithelial cell development (17, 18). Functionally, p63 can bind to p53-DNA binding sites *in vitro* and can activate transcription of p53-responsive promoters.

Whereas p53 family members have distinctive roles, they also have physiological and functional overlapping features. To elucidate how p63 and p53 may be complementary in oral-esophageal squamous epithelial cells, we used a comparison of p53-null and WT mice. Both TAp63 and ΔNp63 are present in the oral-esophageal epithelia with increased expression and staining intensity in p53-null mice compared with age-matched WT littermates. Our data provide evidence for the coexistence of TAp63 and ΔNp63 in basal and suprabasal cells, suggesting a dynamic interplay in their homeostatic control of differentiation (21). It is possible that TAp63 serves as a positive regulator of the switch from proliferating basal cells to differentiating suprabasal cells through the transactivation of p21 and bax. Indeed, p63 has been suggested to be a "marker" of stem or progenitor cells in the basal cell compartment (22). By contrast, ΔNp63 may contribute to the equilibrium between proliferation and differentiation by virtue of

its potential dominant-negative function in modulating promoters such as p21 and bax. Interestingly, this may not be true for all ΔNp63 isoforms in that our data suggest differences between ΔNp63γ and ΔNp63α in modulating p21 promoter activity in oral keratinocytes derived from WT and p53-null mice. Additionally, whereas we find that p21 and bax are expressed in a p53-null background by the TaqMan assay, we can only infer their transactivation *in vivo* by TAp63 which is either not effectively opposed by ΔNp63, or alternatively, ΔNp63 acts to counterbalance even greater TAp63-mediated transactivation of p21 and bax than is detectable. In either context, the expression of p21 and bax in the oral-esophageal epithelia in a p53-null background may help to explain the lack of dysplasia or cancer in these tissues.

In summary, the p53-null mice provide an excellent model in which to study the role of p63 in oral-esophageal squamous epithelia given the importance of p63 in the development and differentiation of squamous epithelia.

## ACKNOWLEDGMENTS

We thank the NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases (P30 DK50306) and its Morphology, Molecular Biology, and Transgenic/Chimeric Mouse Core Facilities. We also thank Dr. Ralph Kent with assistance of the statistical analysis (P01 DE12467), the Deutsche Krebs-hilfe Grant D/96/17197 (to O. G. O.), and the American Digestive Health Foundation Student fellowship (to A. A.). Finally, we thank Hiroshi Nakagawa and Hideki Harada for discussions.

## REFERENCES

1. Steele, R. J., Thompson, A. M., Hall, P. A., and Lane, D. P. The p53 tumour suppressor gene. *Br. J. Surg.*, 85: 1460–1467, 1998.
2. Levine, A. J. p53, the cellular gatekeeper for growth and division. *Cell*, 88: 323–331, 1997.
3. Yang, A., and McKeon, F. p63 and p73: p53 mimics, menaces and more. *Nature Rev. Mol. Cell Biol.*, 1: 199–207, 2000.
4. Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dotsch, V., Andrews, N. C., Caput, D., and McKeon, F. p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. *Mol. Cell*, 2: 305–316, 1998.
5. Kaelin, W. G., Jr. The emerging p53 gene family. *J. Natl. Cancer Inst. (Bethesda)*, 7: 594–598, 1999.
6. Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M., and Ikawa, S. Cloning and functional analysis of human p51, which structurally and functionally resembles p53 (Published erratum in *Nat. Med.*, 4: 982, 1998). *Nat. Med.*, 4: 839–843, 1998.
7. Hall, P., Campbell, S. J., O'Neill, M., Royston, D. J., Nylander, K., Carey, F. A., and Kernohan, N. M. Expression of the p53 homologue p63α and ΔNp63α in normal and neoplastic cells. *Carcinogenesis (Lond.)*, 21: 153–160, 2000.
8. Marin, M. C., and Kaelin, W. G. p63 and p73: old members of a new family. *Biochim. Biophys. Acta*, 1470: M93–M100, 2000.
9. Strano, S., Rossi, M., Fontemaggi, G., Munarriz, E., Soddu, S., Sacchi, A., and Blandino, G. From p63 to p53 across p73. *FEBS Lett.*, 490: 163–170, 2001.
10. Shimada, A., Kato, S., Enjo, K., Osada, M., Ikawa, Y., Kohno, K., Obinata, M., Kanamaru, R., Ikawa, S., and Ishioka, C. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. *Cancer Res.*, 59: 2781–2786, 1999.
11. Augustin, M., Bamberger, C., Paul, D., and Schmae, H. Cloning and chromosomal mapping of the human p53-related KET gene to chromosome 3q27 and its murine homologue Ket to mouse chromosome 16. *Mamm. Genome*, 9: 899–902, 1998.
12. Katoh, I., Aisaki, K.-I., Kurata S.-I., Ikawa, S., and Ikawa, Y. p51A (TAp63g), a p53 homologue, accumulates in response to DNA damage for cell regulation. *Oncogene*, 19: 3126–3130, 2000.
13. Davison, T. S., Vagner, C., Kaghad, M., Ayed, A., Caput, D., and Arrowsmith, C. H. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. *J. Biol. Chem.*, 274: 18709–18714, 1999.
14. Gaidon, C., Lokshin, M., Ahn, J., Zhang, T., and Prives, C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. *Mol. Cell Biol.*, 21: 1874–1887, 2000.
15. Hagiwara, K., McMenamin, M. G., Miura, K., and Harris, C. C. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. *Cancer Res.*, 59: 4165–4169, 1999.
16. Celli, J., Duijff, P., Hamel, B. C., Bamshad, M., Kramer, B., Smits, A. P., Newbury-Ecob, R., Hennekam, R. C., Van Buggenhout, G., van Haeringen, A., Woods, C. G., van Essen, A. J., de Waal, R., Vriend, G., Haber, D. A., Yang, A.,

- McKeon, F., Brunner, H. G., and van Bokhoven, H. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. *Cell*, *99*: 143–153, 1999.
17. Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C., Sharpe, A., Caput, D., Crum, C., and McKeon, F. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. *Nature (Lond.)*, *398*: 714–718, 1999.
  18. Mills, A. A., Zheng, B., Wang, X. J., Vogel, H., Roop, D. R., and Bradley, A. p63 is a p53 homologue required for limb and epidermal morphogenesis. *Nature (Lond.)*, *398*: 708–713, 1999.
  19. Nakagawa, H., Wang, T. C., Zukerberg, L., Odze, R., Togawa, K., May, G. H., Wilson, J., and Rustgi, A. K. The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach. *Oncogene*, *14*: 1185–1190, 1997.
  20. Mueller, A., Odze, R., Jenkins, T. D., Shahsesfai, A., Nakagawa, H., Inomoto, T., and Rustgi, A. K. A transgenic mouse model with cyclin D1 overexpression results in cell cycle, epidermal growth factor receptor, and p53 abnormalities. *Cancer Res.*, *57*: 5542–5549, 1997.
  21. Parsa, R., Yang, A., McKeon, F., and Green, H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. *J. Investig. Dermatol.*, *113*: 1099–1105, 1999.
  22. Pelligrini, G., Dellambra, E., Golisano, O., Martinelli, E., Fantozzi, I., Bondanza, S., Ponzin, D., McKeon, F., and De Luca, M. p63 identifies keratinocyte stem cells. *Proc. Natl. Acad. Sci. USA*, *98*: 3156–3161, 2001.